Although metoclopramide (Reglan, Schwarz) is often used as an antiemetic and an antimigraine therapy, acute akathisia has been linked to the drug. Researchers from Johns Hopkins University, New York University Medical Center, and Bellevue Hospital Center, however, have found that reducing the infusion rate can eliminate this adverse effect.
Researchers gave 36 patients a bolus and 32 patients an infusion. Akathisia developed in six patients in the bolus group (11%) but in none of the 32 patients in the infusion group.
Slowing down the infusion is a simple intervention that may improve patient comfort and satisfaction without a reduction in drug efficacy. The researchers found no difference between the groups in the effectiveness of treatment.
Source: Am J Emerg Med2009;27:475-480